CD3+ Tumor-Infiltrating Lymphocytes in Breast Carcinoma: Their Prognostic Role and Association With Clinical Parameters.

Background Breast carcinoma cases are rising steadily and represent a major cause of mortality and morbidity in India. In response to breast carcinoma, the immune system is activated, resulting in lymphocyte infiltration in and around the tumor nests. This interaction between the tumor and immune system is the basis for studying tumor-infiltrating lymphocytes (TILs). Despite studies on TILs in breast carcinoma, the role of CD3+TILs in predicting patient outcomes remains underexplored. This study aimed to evaluate TILs in breast carcinoma tissues by analyzing CD3 expression through immunohistochemistry (IHC) and examining its association with various prognostic factors, such as histological grade, clinical stage, lymph node status, and hormone receptor status. Methods A study was conducted on 45 breast carcinoma cases, documenting various clinicopathological parameters. IHC staining was performed for estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor (HER2-neu), and CD3 markers on tissue samples. Both intra-tumoral and stromal CD3 TILs were quantified and analyzed in relation to clinicopathological prognostic factors. Results In all 45 breast carcinoma cases, intra-tumoral and stromal CD3 expression was assessed. High stromal CD3 expression is documented in the triple-negative breast tumor. CD3 intra-tumoral expression correlated significantly with tumor size (p < 0.035), ER status (p < 0.036), and PR status (p < 0.036). CD3 stromal expression showed no correlation with any of the prognostic parameters. Conclusion The current study found a strong correlation between CD3 intra-tumoral expression with tumor size, ER and PR status. The findings imply that CD3 may be a significant factor in breast carcinoma prognosis. There were more stromal CD3 TILs in triple-negative breast carcinoma (TNBC) cases. TILs ought to be examined for their capacity as novel prognostic and predictive indicators, especially in cases of invasive breast cancer, such as triple-negative breast carcinoma.

Authors

Institutions

Publication Details

Journal
PubMed
Published
2024-12-01
DOI
https://doi.org/10.7759/cureus.75479
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

CD3+ Tumor-Infiltrating Lymphocytes in Breast Carcinoma: Their Prognostic Role and Association With Clinical Parameters.

Ruchi Chauhan, Vijayalaxmi Patil
1 links
PubMed
Cancer Immunotherapy and Biomarkers
article

CD3+ Tumor-Infiltrating Lymphocytes in Breast Carcinoma: Their Prognostic Role and Association With Clinical Parameters.

Ruchi Chauhan, Vijayalaxmi Patil
article en

Abstract

Background Breast carcinoma cases are rising steadily and represent a major cause of mortality and morbidity in India. In response to breast carcinoma, the immune system is activated, resulting in lymphocyte infiltration in and around the tumor nests. This interaction between the tumor and immune system is the basis for studying tumor-infiltrating lymphocytes (TILs). Despite studies on TILs in breast carcinoma, the role of CD3+TILs in predicting patient outcomes remains underexplored. This study aimed to evaluate TILs in breast carcinoma tissues by analyzing CD3 expression through immunohistochemistry (IHC) and examining its association with various prognostic factors, such as histological grade, clinical stage, lymph node status, and hormone receptor status. Methods A study was conducted on 45 breast carcinoma cases, documenting various clinicopathological parameters. IHC staining was performed for estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor (HER2-neu), and CD3 markers on tissue samples. Both intra-tumoral and stromal CD3 TILs were quantified and analyzed in relation to clinicopathological prognostic factors. Results In all 45 breast carcinoma cases, intra-tumoral and stromal CD3 expression was assessed. High stromal CD3 expression is documented in the triple-negative breast tumor. CD3 intra-tumoral expression correlated significantly with tumor size (p < 0.035), ER status (p < 0.036), and PR status (p < 0.036). CD3 stromal expression showed no correlation with any of the prognostic parameters. Conclusion The current study found a strong correlation between CD3 intra-tumoral expression with tumor size, ER and PR status. The findings imply that CD3 may be a significant factor in breast carcinoma prognosis. There were more stromal CD3 TILs in triple-negative breast carcinoma (TNBC) cases. TILs ought to be examined for their capacity as novel prognostic and predictive indicators, especially in cases of invasive breast cancer, such as triple-negative breast carcinoma.

PubMedVol. 16(12)
Shri BM Patil Medical College (IN)
Openalex Percentile: Top 58%
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

CD3+ Tumor-Infiltrating Lymphocytes in Breast Carcinoma: Their Prognostic Role and Association With Clinical Parameters. — Ruchi Chauhan, Vijayalaxmi Patil · PubMed (2024) | TGRS Research Map | TGRS